

1. Fujisaki S, Ibe S, Hattori J, Shigemi U, Fujisaki S, Shimizu K, Nakamura K, Yokomaku Y, Mamiya N, Utsumi M, Hamaguchi M, Kaneda T.: An 11-year surveillance of HIV type 1 subtypes in Nagoya, Japan *AIDS Res Hum Retroviruses* 25: 15-21, 2009
2. Ibe S, Shigemi U, Sawaki K, Fujisaki S, Hattori J, Yokomaku Y, Mamiya N, Hamaguchi M, Kaneda T.: Analysis of near full-length genomic sequences of drug resistant HIV-1 spreading among therapy-naïve individuals in Nagoya, Japan: aminoacid mutations associated with viral replication activity. *AIDS Res Hum Retroviruses* 24: 1121-1125, 2008
3. 橋本里奈、向井栄一郎、横幕能行、間宮均人、濱口元洋: HIV脳症5例の臨床的特徴と経過. *臨床神経* 48: 173-178, 2008
4. 小池隆夫、他: HIV感染症診断・治療・看護マニュアル 改訂第7版 平成21年12月
5. 小池隆夫、他: 平成21年度北海道HIV/AIDS医療者研修会記録集 平成22年2月
6. Gatanaga H and Oka S.: Successful genotype-tailored treatment with small-dose efavirenz. *AIDS (correspondence)* 23: 433-434, 2009
7. Gatanaga H, Honda H, Tsukada K, Tanuma J, Yazaki H, Honda M, Teruya K, Kikuchi Y, and Oka S.: Detection of HIV-1 load by the Roche COBAS TaqMan assay in patients with previously undetectable load by the Roche COBAS Amplicor Monitor. *Clin Infect Dis (correspondence)* 48: 260-262, 2009
8. Davaalkham J, Unenchimeng P, Baigalmaa C, Oyunbileg B, Tsuchiya K, Hachiya A, Gatanaga H, Nyamkhuu D, and Oka S.: High risk status of HIV-1 in the very low epidemic country, Mongolia, 2007 *Int J STD AIDS* 20: 391-394, 2009
9. Srasuebkul P, Lim PL, Lee MP, Kumarasamy N, Zhou J, Sirisanthana T, Li PC, Kamarulzaman A, Oka S, Phanuphak P, Vonthanak S, Merati TP, Chen YM, Sungkanuparph S, Tau G, Zhang F, Lee CK, Ditangco R, Pujari S, Choi JY, Smith J, and Law MG. : Short-term clinical disease progression in HIV-infected patients receiving combination antiretroviral therapy: results from the TREAT Asia HIV observational database. *Clin Infect Dis* 48: 940-950, 2009
10. Mocroft A, Wyatt C, Szczech L, Neuhaus J, El-Sadr W, Tracy R, Kuller L, Shlipak M, Angus B, Klinker H, Ross M; INSIGHT SMART Study Group (Oka S as a principal investigator of the Sydney Regional Coordinating Center): Interruption of antiretroviral therapy is associated with increased plasma cystatin C. *AIDS* 23: 71-82, 2009
11. Kamimura M, Watanabe K, Kobayakawa M, Mihara F, Edamoto Y, Teruya K, Kikuchi Y, and Oka S: Absorption of lopinavir is limited within 35cm distance from Treiz ligament in the jejunum. *Intern Med (Case Report)* 48: 1103-1104, 2009, Epub 2009 Jun 15
12. Zheng N, Fujiwara M, Oka S, and Takiguchi M.: Strong ability of Nef-specific CD4⁺ cytotoxic T cells to suppress HIV-1 replication in HIV-1-infected CD4⁺ T cells and macrophages. *J Virol* 83: 7668-7677, 2009, Epub 2009 May 20.
13. Zhou J, Elliott J, Li PC, Lim PL, Kiertiburanakul S, Kumarasamy N, Merati TP, Pujari S, Chen YM, Phanuphak P, Vonthanak S, Sirisanthana T, Sungkanuparph S, Lee CK, Kamarulzaman A, Oka S, Zhang F, Tau G, and Ditangco R.: Risk and prognostic significance of tuberculosis in patients from The TREAT Asia HIV Observational Database. *BMC Infect Dis* 9: 46, 2009
14. Honda H, Gatanaga H, Matsumura J, Kamimura M, Goto K, Tsukada K, Honda M, Teruya K, Kikuchi Y, and Oka S.: Favorable usage of non-boosted fosamprenavir in patients treated with warfarin. *Int J STD AIDS (Letters to the Editor)* 20: 441 , 2009
15. Yazaki H, Goto N, Uchida K, Kobayashi T, Gatanaga H, and Oka S: Outbreak of *Pneumocystis jiroveci* pneumonia in renal transplant recipients: *P jiroveci* is contagious to the susceptible host. *Transplantation* 88: 380-385, 2009
16. Zhou J, Li PC, Kumarasamy N, Boyd M, Chen YMA, Sirisanthana T, Sungkanuparph S, Oka S, Tau G, Phanuphak P, Saphonn V, Zhang FJ, Kamarulzaman A, Lee CK, Ditango R, Merati TP, Lim PL, Choi JY, and Pujari S on behalf of the Treat Asia HIV Observational Database.: Deferred modification of anti-retroviral regimen following documented treatment failure in Asia: results from The TREAT Asia HIV Observational Database (TAHOD). *HIV Med* Epub Jul 6, 2009.

17. Davaalkham J, Tsuchiya K, Gatanaga H, Nyamkhuu D, and Oka S.: Allele and Genotype Frequencies of Cytochrome P450 2B6 Gene in a Mongolian Population *Drug Metab Disp.* 37: 1991-1993, 2009, Epub Jul 6, 2009.
18. Watanabe T, Yasuoka A, Honda H, Tanuma J, Yazaki H, Tsukada K, Honda M, Gatanaga H, Teruya K, Tachikawa N, Kikuchi Y, and Oka S.: Serum (1-3) β -D-glucan as a non-invasive useful adjunctive diagnostic marker for *Pneumocystis pneumonia* in patients with human immunodeficiency virus. *Clin Infect Dis* 49: 1128-1131, 2009. Epub Sep 2, 2009
19. Watanabe K, Teruya K, Kikuchi Y, Oka S.: Successful treatment of ulcerous skin lesion caused by mistaken intradermal injection of BCG (Bacille de Calmette et Guerin) vaccine with anti-tuberculous drugs and systemic administration of corticosteroid. *Intern Med* 48: 1323-5132, 2009. Epub Aug 3, 2009
20. Hashimoto M, Kitano M, Honda K, Koizumi H, Dohki S, Oka S, Takiguchi M.: Selection of escape mutation by Pol154-162-specific cytotoxic T cells among chronically HIV-1-infected HLA-B*5401-positive individuals *Hum Immunol* 71: 123-127, 2010, Epub 2009 Nov 2
21. INSIGHT-ESPRIT Study Group (Oka S as a Regional Principal Investigator): Interleukin-2 therapy in patients with HIV infection. *N Engl J Med* 361: 1548-59, 2009
22. Tsukada K, Teruya K, Tasato D, Gatanaga H, Kikuchi Y, and Oka S: Raltegravir-associated perihepatitis and peritonitis: a single case report. *AIDS (correspondence)* 24: 160-161, 2010
23. Watanabe K, Honda M, Watanabe T, Tsukada K, Teruya K, Kikuchi Y, Oka S, and Gatanaga H.: Emergence of raltegravir-resistant HIV-1 in the central nerve system. *Int J STD AIDS (case report)* in press
24. H Gatanaga, Ode H, Hachiya A, Hayashida T, Sato H, Takiguchi M, and Oka S.: Impact of HLA-B*51-restricted CTL Pressure on Mutation Patterns of Non-nucleoside Reverse Transcriptase Inhibitor Resistance. *AIDS (Fast Track)* in press
25. Sakai K, Gatanaga H, Takata H, Oka S, and Takiguchi M.: Comparison of CD4⁺ T-cell-subset distribution in chronically infected HIV⁺ patients with various CD4 nadir counts *Microb Infect* 2010 Jan 29. Epub ahead of print
26. Gatanaga H, Ode H, Hachiya A, Hayashida T, Sato H, Oka S.: Combination of V106I and V179D Polymorphic Mutations in Human Immunodeficiency Virus Type 1 Reverse Transcriptase Confers Resistance to Efavirenz and Nevirapine but not to Etravirine. *Antimicrob Agents Chemother* 2010 Feb 1. Epub ahead of print
27. 上平朝子: HIV感染症患者を専門医に紹介するとき これでわかる HIV/AIDS診療の基本, 南江堂 133-143, 2009
28. 中川正法、上平朝子、橋本里奈、岸田修二、三浦義治、邢惠琴、出雲周二: HAARTとNeuroAIDS日本エイズ学会誌 11(2): 81-91, 2009
29. Minami R, Takahama S, Ando H, Miyamura T, Suematsu E, and Yamamoto M.: Human Herpesvirus 8 DNA load in the leukocytes correlates with thrombocytopenia in HIV-1 infected individuals. *AIDS Res Hum Retroviruses* 25(1): 1-8, 2009
30. Minami R, Yamamoto M, Takahama S, Ando H, Miyamura T, Suematsu E.: High molecular weight form of adiponectin in HIV-infected Japanese individuals based on in vivo and in vitro analyses. *Intern Med.* 48(20): 1799-1875, 2009
31. 南 留美、高濱宗一郎、安藤仁、山本政弘: 治療後ウエスタンブロット法にて抗HIV抗体が陰性化し持続している HIV感染症の一例 *感染症学会雑誌* 83(3): 251-255, 2009
32. 前田憲昭、他: 口腔管理ノート 2009-20 2010
33. 前田憲昭、今井健一: HIV感染症から口腔の重要性を考え *日本歯科評論* 69(11): 168-170, 2009
34. 山中京子: HIV感染症に対するカウンセリング体制の現状および課題に関する研究—中核拠点病院診療医に対するアンケート調査結果を中心に— *日本性科学会誌* 27(1): 35-48, 2009. 9
35. 田中千枝子、本名靖: HIV/AIDS患者に対する医療ソーシャルワーカーの地域連携行動 *日本福祉大学社会福祉論集* 121: 43-54, 2009

36. 井出博生、赤羽学、白阪琢磨、今村知明: HIV診療に係る原価の実態調査 日本エイズ学会誌 12(1), In press, 2010
37. Kawashima Y, Pfafferott K, Duda A, Matthews P, Addo M, Gatanaga H, Fujiwara M, Hachiya A, Kizumi H, Kuse N, Oka S, Brumme Z, Brumme C, Brander C, Allen T, Kaslow R, Tang J, Hunter E, Allen S, Mulenga J, Branch S, Roach T, John M, Mallal S, Heckerman D, Frater J, Prendergast A, Crawford H, Leslie A, Prado J, Ndung'u T, Phillips R, Harrigan R, Walker B, Takiguchi M, and Goulder P.: Adaptation of HIV-1 to HLA I. *Nature* 458: 641-645, 2009, Epub 2009 Feb 25.
38. Hachiya A, Shimane K, Sarafianos SG, Kodama EN, Sakagami Y, Negishi F, Koizumi H, Gatanaga H, Matsuoka M, Takiguchi M, Oka S.: Clinical relevance of substitutions in the connection subdomain and RNase H domain of HIV-1 reverse transcriptase from a cohort of antiretroviral treatment-naïve patients. *Antiviral Res* 82: 115-121, 2009
39. Ghosh, AK, Gemma S, Simoni E, Baldrige A, Walters, DE, Ide K, Tojo Y, Koh Y, Amano M, and Mitsuya H.: Synthesis and biological evaluation of novel allophenylnorstatine-based HIV-1 protease inhibitors incorporating high affinity P2-ligands. *Bioorg. Med. Chem. Lett.* 20: 1241-6, 2010
40. Ghosh AK, Leshchenko-Yashchuk S, Anderson DD, Baldrige A, Noetzel M, Miller HB, Tie Y, Wang YF, Koh Y, Weber IT, Mitsuya H.: Design of HIV-1 protease inhibitors with pyrrolidinones and oxazolidinones as novel P1'-ligands to enhance backbone-binding interactions with protease: synthesis, biological evaluation, and protein-ligand X-ray studies. *J. Med. Chem.* 52: 3902-14, 2009
41. Fujimoto H, Higuchi M, Watanabe H, Koh Y, Ghosh AK, Mitsuya H, Tanoue N, Hamada A, and Saito H.: P-glycoprotein mediates efflux transport of darunavir in human intestinal Caco-2 and ABCB1 gene-transfected renal LLC-PK1 cell lines. *Biol. Pharm. Bull.* 32: 1588-93, 2009
42. Ghosh AK, Sarang Kulkarni S, Anderson DD, Hong L, Baldrige A, Wang Y-F, Chumanovich AA, Kovalevsky AY, Tojo Y, Koh Y, Tang J, Weber IT, and Mitsuya H.: Design, synthesis, protein-ligand X-ray structures and biological evaluation of a series of novel macrocyclic HIV-1 protease inhibitors to combat drug-resistance. *J. Med.Chem.* 52: 7689-705, 2009
43. Hattori S, Ide K, Nakata H, Harada H, Suzu S, Ashida N, Kohgo S, Hayakawa H, Mitsuya H, and Okada S.: Potent activity of a nucleoside reverse transcriptase inhibitor, 4'-ethynyl-2-fluoro-2'-deoxyadenosine, against HIV-1 infection in Hu-PBMC-NOD/SCID/JAK3null (NOJ) mouse model. *Antimicrob. Agents Chemother.* 53: 3887-93, 2009
44. Das D, Koh Y, Tojo Y, Ghosh AK, and Mitsuya H.: Prediction of Potency of Protease Inhibitors Using Free Energy Simulations with Polarizable Quantum Mechanics-Based Ligand Charges and a Hybrid Water Model. *J. Chem. Inf. Model* 49: 2851-62, 2009
45. Michailidis E, Bruno Marchand B, Ei-Ichi Kodama E-I, Kamendra Singh K, Matsuoka M, Ashida N, Kirby K, Ryan EM, Sawani AM, 1, Eva Nagy E, Mitsuya H, Parniak MP, and Sarafianos SG.: Mechanism of inhibition of HIV-1 reverse transcriptase by 4'-ethynyl-2-fluoro-deoxyadenosine triphosphate, a translocation defective reverse transcriptase inhibitor. *J. Biol. Chem.* 284: 35681-91, 2009
46. Aoki M, Venzon DJ, Koh Y, Aoki-Ogata H, Miyakawa T, Yoshimura K, Maeda K, Mitsuya H.: Non-cleavage Site Gag Mutations in Amprenavir-resistant HIV-1 Predispose HIV-1 to Rapid Acquisition of Amprenavir Resistance But Delays Development of Resistance to Other Protease Inhibitors. *J Virol.* 83: 3059-68, 2009
47. Koh Y, Das D, Leschenko S, Nakata H, Ogata-Aoki H, Amano M, Nakayama M, Ghosh AK, Mitsuya H.: GRL-02031: A Novel Nonpeptidic Protease Inhibitor (PI) Containing A Stereochemically Defined Fused Cyclopentanyltetrahydrofuran (Cp-THF) Potent Against Multi-PI-Resistant HIV-1 In Vitro. *Antimicrob. Agents Chemother* 53: 997-1006, 2009
48. Shou Matsuyama, Ay Aydan、 Hirotoaka Ode, Masayuki Hata, Wataru Sugiura and Tyuji Hoshino.: Structural and energetic analysis on the complexes of clinically isolated subtype C HIV-1 proteases and approved inhibitors by molecular dynamics simulation. *J.Phys.Chem.B* 114: 521-530, 2010
49. Land S, Cunningham P, Zhou J, Frost K, Katzenstein D, Kantor R, Chen YM, Oka S, DeLong A, Sayer D, Smith J, Dax EM, Law M; TAQAS Laboratory Network.: TREAT Asia Quality Assessment Scheme

(TAQAS) to standardize the outcome of HIV genotypic resistance testing in a group of Asian laboratories. *J Virol Methods*. 159(2): 185-93, Aug, 2009

50. Hasegawa N, Sugiura W, Shibata J, Matsuda M, Ren F, Tanaka H.: Inferring within-patient HIV-1 evolutionary dynamics under anti-HIV therapy using serial virus samples with vSPA. *BMC Bioinformatics*. 10(1): 360, Oct 29, 2009
51. Iwatani Y, Chan DS, Liu L, Yoshii H, Shibata J, Yamamoto N, Levin JG, Gronenborn AM, Sugiura W.: HIV-1 Vif-mediated ubiquitination/degradation of APOBEC3G involves four critical lysine residues in its C-terminal domain. *Proc Natl Acad Sci U S A*. 106(46): 19539-44, Nov 17, 2009

An 11-Year Surveillance of HIV Type 1 Subtypes in Nagoya, Japan

Seiichiro Fujisaki, Shiro Ibe, Junko Hattori, Urara Shigemi, Saeko Fujisaki, Kayoko Shimizu, Kazuyo Nakamura, Yoshiyuki Yokomaku, Naoto Mamiya, Makoto Utsumi, Motohiro Hamaguchi, and Tsuguhiro Kaneda

Abstract

To monitor active HIV-1 transmission in Nagoya, Japan, we have been determining the subtypes of HIV-1 infecting therapy-naive individuals who have newly visited the Nagoya Medical Center since 1997. The subtypes were determined by phylogenetic analyses using the base sequences in three regions of the HIV-1 genes including *gag p17*, *pol protease (PR)* and *reverse transcriptase (RT)*, and *env C2V3*. Almost all HIV-1 subtypes from 1997 to 2007 and 93% of all HIV-1 isolates in 2007 were subtype B. HIV-1 subtypes A, C, D, and F have been detected sporadically since 1997, almost all in Africans and South Americans. The first detected circulating recombinant form (CRF) was CRF01_AE (11-year average annual detection rate, 7.7%). Only two cases of CRF02_AG were detected in 2006. A unique recombinant form (URF) was first detected in 1998 and the total number of URFs reached 25 by year 2007 (average annual detection rate, 4.7%). Eleven of these 25 were detected from 2000 to 2005 and had subtypes AE/B/AE as determined by base sequencing of the *gag p17*, *pol PR* and *RT*, and *env C2V3* genes (average annual detection rate, 3.7%). Unique subtype B has been detected in six cases since 2006. All 17 of these patients were Japanese. Other recombinant HIV-1s have been detected intermittently in eight cases since 1998. During the 11-year surveillance, most HIV-1s in Nagoya, Japan were of subtype B. We expect that subtype B HIV-1 will continue to predominate for the next several years. Active recombination between subtype B and CRF01_AE HIV-1 and its transmission were also shown.

Introduction

THE TOTAL NUMBER OF HIV-1-INFECTED INDIVIDUALS and the prevalence of HIV-1 in Japan were 13,842 and 0.01%, respectively, at the end of 2007, which is far less than the number and prevalence in other Asian countries.¹⁻⁶ However, the number of newly infected patients per year was still increasing in Japan in 2007, when it reached 1448. One-hundred and twenty-five (8.6%) new patients were identified in Aichi prefecture in the same year. The total number of HIV-1-infected individuals and the prevalence of HIV in Aichi prefecture in 2007 were 725 and 0.01%, respectively. The number of newly infected individuals is expected to increase further. Therefore, the rapid increase in the number of HIV-1-infected individuals and changes in HIV-1 subtype populations are matters of great concern.

The most prevalent HIV-1 subtype in the world is subtype C (50%) followed by A (12%), B (10%), G (6%), and D (3%).^{7,8} In addition, there are circulating recombinant forms (CRFs), such as CRF01_AE, CRF02_AG, and other recombi-

nant viruses. The prevalent HIV-1 subtypes in China, Japan's largest neighbor, are circulating B/C recombinant forms, CRF07_BC, and CRF08_BC, accounting for 50% of the HIV-infected population, and subtype B HIV-1 accounting for 32%.⁹ In contrast, the most prevalent HIV-1 strains in Japan are subtype B (83.1%) and CRF01_AE (12.4%) according to the nationwide surveillance.¹⁰ It is clear that the distribution of HIV-1 strains is very different in Japan than in the rest of the world. However, as subtypes were determined from the base sequence of the *pol protease (PR)* and *reverse transcriptase (RT)* genes, we could not identify recombinant HIV-1 subtypes.

To study the trend of HIV-1 subtypes and the emergence of recombinant HIV-1 subtypes in Nagoya, Japan, we selected the *gag p17*, *env C2V3*, and *PR to RT* gene. We determined the base sequences of these genes from 2003; the subtypes of HIV-1 samples from 1997 to 2002 were retrospectively determined by the same method. Finally, this study aimed to clarify the genetic changes in HIV-1 subtypes by monitoring the sequences of HIV-1 subtypes that infected therapy-naive patients between 1997 and 2007.

Clinical Research Center, National Hospital Organization Nagoya Medical Center (Tokai Area Central Hospital for AIDS Treatment and Research), Nagoya, Aichi 460-0001, Japan.

TABLE 1. SUBTYPE DISTRIBUTION OF THERAPY-NAIVE HIV-1-INFECTED PATIENTS

	Total	A	B	C	D	F	CRF01_AE	CRF02_AG	Other recombinants
Number of patients	534	10 (1.9%)	440 (82.4%)	11 (2.1%)	1 (0.2%)	4 (0.7%)	41 (7.7%)	2 (0.4%)	25 (4.7%)
Age	37	31	37	38	32	24	40	37	35
Age Range	17-73	20-40	17-73	22-66	—	21-28	20-69	33-41	20-53
CD4 ⁺ T cells (cells/ μ l)	280	305	278	291	418	468	246	289	264
Average Range	0-1508	60-1003	0-1508	7-545	—	278-909	2-1200	210-367	1-716
Viral load (copies/ml)	3.1 $\times 10^5$	1.8 $\times 10^5$	3.3 $\times 10^5$	8.6 $\times 10^4$	2.5 $\times 10^4$	2.2 $\times 10^4$	2.7 $\times 10^5$	5.1 $\times 10^4$	2.9 $\times 10^5$
Average Range	1.0 $\times 10^2$ -1.3 $\times 10^7$	4.4 $\times 10^2$ -1.1 $\times 10^6$	1.0 $\times 10^2$ -1.3 $\times 10^7$	6.1 $\times 10^2$ -4.3 $\times 10^5$	—	2.1 $\times 10^3$ -4.5 $\times 10^4$	7.8 $\times 10^2$ -2.8 $\times 10^6$	4.4 $\times 10^4$ -5.7 $\times 10^4$	2.8 $\times 10^2$ -2.0 $\times 10^6$
Clinical phase ^a									
AC	370	6	302	9	1	4	25	2	21
ARC	37	2	32	0	0	0	3	0	0
AIDS	127	2	106	2	0	0	13	0	4

^aAC, asymptomatic carrier; ARC, AIDS-related complex.

Materials and Methods

Patients

We enrolled 534 therapy-naive HIV-1-infected patients who initially attended our HIV-1 clinic at Nagoya Medical Center in Nagoya, Japan, between June 1997 and December 2007 and gave their written, informed consent to participate in our study. Our research protocol was approved by the ethical committee in our hospital. The samples of this study were the same ones used for drug resistance testing, which was conducted in almost all therapy-naive individuals at their initial visit. The data, including age, nationality, sexual orientation, number of CD4-positive T cells, and viral load, were obtained from medical records.

Patient coverage by Nagoya Medical Center

Nagoya Medical Center is located in Nagoya City, the capital of Aichi prefecture, and is the central hospital for AIDS treatment and research in the Tokai area (which includes the Aichi, Mie, Gifu, and Shizuoka prefectures).

Amplification of HIV-1 DNA fragments and determinations of DNA sequences

HIV-1 RNA was extracted from plasma samples using a QIAamp viral RNA Mini Kit (QIAGEN, Tokyo, Japan). The DNA fragments were amplified by reverse transcription-nested polymerase chain reaction (RT-nested PCR) using the Superscript one-step RT-PCR system (Invitrogen, Tokyo, Japan) and LA Taq polymerase (Takara, Shiga, Japan). The primers used for DNA amplification were as follows. The *gag* fragment containing the region between *gag p17* and *p24* (codons 1-147 encoding *gag-pol polyprotein*) was amplified by RT-PCR with the primer set of 172A (5'-ATC TCT AGC AGT GGC GCC CGA ACA G-3') and 173B (5'-CTG ATA ATG CTG AAA ACA TGG GTA T-3').¹¹ 174A (5'-CTC TCG ACG CAG GAC TCG GCT TCG T-3') and 175B (5'-CCC ATG CAT TCA AAG TTC TAG GTG A-3') were used for nested PCR. The *pol* fragments containing the regions encoding *gag-pol polyprotein* (codons 425-500), *PR* (codons 1-99), and *RT* (codons 1-349) were amplified by RT-PCR with primers of K1 (5'-AAG GGC TGT TGG AAA TGT GG-3') and U13 (5'-CCC ACT CAG GAA TCC AGG T-3').¹² K4 (5'-GAA AGG AAG GAC ACC AAA TGA-3') and U12 (5'-CTC ATT CTT GCA TAT TTT CCT GTT-3') were used for nested PCR. The *env* fragment containing the region encoding *env C2V3* (codons 249-375) was amplified by RT-PCR with primers of 106A (5'-CAT ACA TTA TTG TGC CCC GGC TGG-3') and 17B (5'-AGA AAA ATT CCC CTC TAC AAT TAA-3').¹¹ 14A (5'-AAT GTC AGC TCA GTA CAA TGC ACA C-3') and 10B (5'-ATT TCT GGG TCC CCT CCT GAG G-3') were used for nested PCR. These are in-house primers capable of amplifying the target genes of different HIV-1 subtypes. The *gag*, *pol*, and *env* gene fragments were not amplified in RT-nested PCR using the above-mentioned primers in four, five, and nine cases, respectively. In such cases, different primer sets were used (not shown). Thus, amplified cDNAs were successfully obtained in all cases.

An HIV-1 DNA control, in which reverse transcriptase was omitted in the RT-PCR, was run in parallel with RT-PCR to control for the absence of genomic DNA. The PCR products were purified using the QIAGEN Gel Extraction Kit

(QIAGEN). A labeling reaction for DNA sequencing was performed using the same primers used for the PCR reactions as well as the BigDye terminator v1.1 cycle sequencing kit (Applied Biosystems, Tokyo, Japan), and then labeled DNA fragments were purified on a AutoSeq G-50 column (GE Healthcare, Tokyo, Japan). The samples were analyzed by direct sequencing and electropherograms were obtained using an ABI PRISM 310 Genetic Analyzer (Applied Biosystems). DNA sequences were analyzed using Sequencing Analysis V3.7 (Applied Biosystems) and SeqScape V2.5 (Applied Biosystems).

Subtype determination

Sequences were analyzed and grouped into subtypes by phylogenetic tree construction. Phylogenetic analysis using nucleotide sequences of *gag* fragments from 534 therapy-naive patients was performed using the 62 reference HIV-1 sequences derived from the Los Alamos National Laboratory database.¹³ The 62 sequences represent all subtypes of the major groups and 18 CRFs. Independent analysis was done using both *pol* fragments and *env* fragments. Sequences

were aligned using CLUSTAL W software in MEGA software version 3.1. Evolutionary distances were calculated using the same software. Phylogenetic trees were constructed by the neighbor-joining method based on distances calculated with Kimura's two-parameter algorithm. The reliabilities of the branching patterns were tested by bootstrap analysis with 1000 replicates.

Results

HIV-1 subtypes in the last 11 years in Nagoya

Subtype B was the most prevalent subtype, identified in 440 out of 534 patients (82.4%, Table 1 and Fig. 1). The largest number, 388, was found in Japanese and the next largest, 45, in South Americans (Table 2). Of the total number, 319 were identified in Japanese men who have sex with men (MSM) and 14 in South American MSM. Of note, the 72.5% infected with subtype B HIV-1 were Japanese MSM. Infection with subtypes A, C, D, and F was detected in 10 individuals (seven Africans, one East European, and two Japanese), 11 individuals (two Africans, two South Americans, two Southwest




FIG. 1. Subtypes of HIV-1 found in therapy-naive infected patients in Nagoya Medical Center from 1997 to 2007 (upper panel). The numbers of patients (bars) and their proportions (% in parentheses) are shown. The numbers of patients and their nationalities (indicated by a color: Japan, red; East Asia, green; Southwest Asia, blue; South America, orange; North America, pink; Eastern Europe, black; Africa, uncolored) are given in the lower panel.

TABLE 2. NATIONALITIES AND SEXUAL ORIENTATIONS OF THERAPY-NAIVE HIV-1-INFECTED PATIENTS BY SUBTYPES^a

	Total	A	B	C	D	F	CRF01_AE	CRF02_AG	Other recombinants
Nationalities									
Japan	439 (420, 340)	2 (0, 0)	388 (381, 319)	5 (1, 1)	0	0	23 (20, 2)	2 (0, 0)	19 (18, 18)
East Asia	6 (4, 4)	0	4 (4, 4)	0	0	0	1 (0, 0)	0	1 (0, 0)
Southwest Asia	18 (9, 0)	0	1 (0, 0)	2 (1, 0)	0	0	15 (8, 0)	0	0
East Europe	2 (0, 0)	1 (0, 0)	0	0	0	0	0	0	1 (0, 0)
North America	2 (2, 2)	0	2 (2, 2)	0	0	0	0	0	0
South America	55 (36, 15)	0	45 (31, 14)	2 (1, 0)	0	4 (1, 0)	2 (1, 0)	0	2 (2, 1)
Africa	12 (9, 0)	7 (5, 0)	0	2 (1, 0)	1 (1, 0)	0	0	0	2 (2, 0)

^aThe left and right numbers in parentheses are the numbers of males and MSMs, respectively.

Asians, and five Japanese), one African, and four South Americans, respectively. In foreigners, this distribution of HIV-1 subtypes represents the distribution of subtypes commonly found in the immigrants' region of origin.¹⁴⁻²⁰ However, subtypes A and C were detected mostly in Japanese females who seemed to have acquired the infection from foreign partners in Japan.

As for circulating recombinant forms (CRFs), CRF01_AE was detected in 41 individuals (7.7%), including 23 Japanese (18 non-MSM, two MSM, and three females) and 18 foreigners (nine non-MSM and nine females). Considering that only four individuals (two Japanese males, one Japanese female, and

one South Asian female) were intravenous drug users, CRF01_AE has mainly spread through heterosexual contact in Nagoya. CRF02_AG was detected in two individuals (0.4%) in 2006 (Fig. 2).

Among other recombinant forms, the most frequent was AE/B/AE, found in 11 Japanese MSM. A unique subtype B HIV-1 strain that possessed subtype D fragments in the *gag* and *env* regions was also detected in six Japanese MSM. As for other recombinants, A/D/A, D/D/A, and AE/B/B were each identified in two individuals and A/B/A and B/B/F were each identified in one. Thirteen intravenous drug users (2.4%) were included: two male Japanese with subtype B, one female




FIG. 2. Recombinant HIV-1s detected in therapy-naive patients in Nagoya Medical Center (upper panel). The bars indicate the number of recombinant HIV-1s detected from 1997 to 2007. The number of patients and their nationalities (indicated by J, Japan; EA, East Asia; SAs, Southwest Asia; SAm, South America; A, Africa; NA, North America; EE, Eastern Europe) are shown in the lower panel.

Japanese with CRF01_AE, four MSM with a unique subtype B, two male South Americans with subtype B, and two male and one female Southwest Asians with CRF01_AE.

The change of HIV-1 detection rates

The rate of subtype B detection, the most frequently detected HIV-1 subtype in the Nagoya Medical Center, increased to 93% in 2007 (Fig. 1). During this period, the absolute number of individuals with subtype B HIV-1 also increased. On the other hand, the number of individuals infected with non-B HIV-1 strains fluctuated between 7 and 15 after the year 2000. Major subtypes A, C, D, and F were sporadically detected (only two or three cases per year since 2004). The most frequently detected circulating recombinant HIV-1 was CRF01_AE, which was detected every year from 1997 to the present, except for 1999 (Fig. 2). About half of these

infections were in Japanese and the other half were in Southwest Asians. No increase in the number of infections by this virus has been observed. The increase in the number of HIV-1-infected cases, especially of subtype B, during the past 11 years reflected the scaling up of clinical services as well as the increase in HIV-1 transmission.

Active recombination between subtype B and CRF01_AE HIV-1

The A/D/A recombinant was first detected in 1998 (Fig. 2), and unique recombinant forms (URFs) have been detected in all years except 1999. The AE/B/AE recombinant, the most frequently detected URF, had been detected between 2000 and 2005, and the accumulated number of cases with this virus was 11. A unique subtype B HIV-1 was detected in five patients and one patient in 2006 and 2007, respectively.




FIG. 3. Phylogenetic tree analyses of 11 recombinant AE/B/AE HIV-1s. Trees were constructed using nucleotide base sequences of *gag p17* (A), *pol PR to RT* (B), and *env C2V3* (C) gene regions. The base sequences of the *gag p17* and *env C2V3* genes of 41 CRF01_AE HIV-1s and those of the *pol PR to RT* gene of 440 subtype B HIV-1s in this study (Table 1) as well as 39 reference sequences obtained from the Los Alamos database were used for these analyses. Clustered AE/B/AE recombinant HIV-1s indicated by red, blue, and green circles are framed. Red circles represent HIV-1s that form a cluster in all trees. Green circles represent HIV-1s that form a cluster only in trees with *gag* and *env* genes. Blue circles represent HIV-1s that form a cluster only in trees with *gag* and *pol* genes. Candidate HIV-1s with subtype B or CRF01_AE accounting for AE/B/AE recombinant formation are depicted by open triangles (B) and open circles (A and C), respectively.

The detection of one A/D/A, one D/D/A, two AE/B/B, one A/B/A, and one B/B/F was sporadic from 2001 to 2004. The A/D/A, D/D/A, AE/B/B, A/B/A, B/B/F, and unique B recombinants may have been brought from foreign countries because no candidate sequences indicating the origin of A, D, F, and CRF01_AE have been found. Of course, patients infected with these recombinant viruses may have been partners in a sexual network with less access to medical care. Nine viruses of the AE/B/AE recombinant form (represented with red circles in Fig. 3) were clustered in three separate phylogenetic analyses of the *gag p17*, *env C2V3*, and *pol PR to RT* genes, indicating that they were closely related. In addition, CRF01_AE of patient 115 was positioned in the same cluster of *gag* and *env* sequences mentioned above, and subtype B of patient 135 in the same cluster of *pol* sequence, suggesting this AE/B/AE recombinant form may be originated from these two viruses.

Discussion

In this study, the emergence and transmission of recombinant HIV-1s were analyzed in detail by determining base sequences of major segments of three genes: *gag p17*, *pol PR to RT*, and *env C2V3*. The subtypes of HIV-1 strains prevalent in the Nagoya Medical Center for the past 11 years were B (82.4%), CRF01_AE (7.7%), C (2.1%), A (1.9%), F (0.7%), CRF02_AG (0.4%), D (0.2%), and other recombinant forms (4.7%). This result was similar to the result of a nationwide study (using only the *pol PR to RT* gene region to determine subtypes¹⁰), which found that only 5% of the total cases were due to recombinant forms. Worldwide, subtype C is the most prevalent HIV-1 subtype (50% of all cases).^{8,9} This means the situation in Nagoya, Japan is quite different from that in other parts of the world, especially from that in Africa.

The recombinant HIV-1s, in addition to CRF01_AE and CRF02_AG, include 11 AE/B/AE, six unique subtype B recombinants possessing short D fragments in *gag* and *env* genes, two A/D/A, two D/D/A, two AE/B/B, one A/B/A, and one B/B/F. Among these seven, all except AE/B/AE appear to be immigrant types. Only the AE/B/AE type seems to be a newly emerged recombinant in our area. As subtype B was the predominant HIV-1 subtype and CRF01_AE was the second-most prevalent HIV-1 recombinant in Nagoya, we have speculated that a novel recombinant HIV-1 between subtype B and CRF01_AE will emerge in this area. The methodology for subtype determination using the base sequences of *gag p17*, *pol PR to RT*, and *env C2V3* genes is useful at the moment; however, to clarify the gene structure of these recombinant viruses, analysis of the full sequence and then computational analyses are required. Use of this approach revealed that the gene structure of AE/B/AE type recombinants found in this study is novel and differs from that of CRF15_01B, CRF33_01B, and CRF34_01B (i.e., CRFs resulting from recombination between subtype B and CRF01_AE HIV-1 found in Malaysia and Thailand).²¹⁻²³ The finding of two viruses with genes for both subtype B and CRF01_AE, which are the candidate origins of this AE/B/AE recombinant, supported our hypothesis of emerging recombinants. The number of HIV-1-infected individuals as well as the frequency of drug-resistant HIV-1 in therapy-naïve individuals have increased, strongly implying that this increasing tendency will continue in Nagoya, Japan.^{24,25} We will pursue this kind

of surveillance to obtain information needed for suppressing the spread of HIV-1 infection.

Sequence Data

The base sequences of HIV-1 subtypes are registered in the DNA databank of Japan (DDBJ) as AB442228–AB443428 and AB356098–AB356499.

Acknowledgments

This study was supported by a grant for research on HIV/AIDS from the Ministry of Health, Labour, and Welfare of Japan (No. H19-AIDS-028). Junko Hattori and Saeko Fujisaki are research residents of the Japanese Foundation for AIDS Prevention.

Disclosure Statement

No competing financial interests exist.

References

1. Japanese Foundation of AIDS Prevention: <http://www.jfap.or.jp/english/index.htm>.
2. Wu Z, Sun X, Sullivan SG, and Detels R: HIV testing in China. *Science* 2006;312:1475–1476.
3. Wu Z, Sullivan SG, Wang Y, *et al.*: Evolution of China's response to HIV/AIDS. *Lancet* 2007;369:679–690.
4. Steinbrook R: HIV in India—a complex epidemic. *N Engl J Med* 2007;356:1089–1093.
5. Wirachsilp P, Kantakamalakul W, Foongladda S, *et al.*: Surveillance of subtype and genetic variation of the circulating strains of HIV-1 in Thailand. *Southeast Asian J Trop Med Public Health* 2007;38:814–827.
6. Chang SY, Sheng WH, Lee CN, *et al.*: Molecular epidemiology of HIV type 1 subtypes in Taiwan: Outbreak of HIV type 1 CRF07_BC infection in intravenous drug users. *AIDS Res Hum Retroviruses* 2006;22:1055–1066.
7. Hemelaar J, Gouws E, Ghys PD, and Osmanov S: Global and regional distribution of HIV-1 genetic subtypes and recombinants in 2004. *AIDS* 2006;20:W13–23.
8. McCutchan FE: Global epidemiology of HIV. *J Med Virol* 2006;78:S7–S12.
9. Zhong P, Pan Q, Ning Z, *et al.*: Genetic diversity and drug resistance of human immunodeficiency virus type 1 (HIV-1) strains circulating in Shanghai. *AIDS Res Hum Retroviruses* 2007;23:847–856.
10. Gatanaga H, Ibe S, Matsuda M, *et al.*: Drug-resistant HIV-1 prevalence in patients newly diagnosed with HIV/AIDS in Japan. *Antiviral Res* 2007;75:75–82.
11. Kato K, Shiino T, Kusagawa S, *et al.*: Genetic similarity of HIV type 1 subtype E in a recent outbreak among injecting drug users in northern Vietnam to strains in Guangxi Province of southern China. *AIDS Res Hum Retroviruses* 1999;15:1157–1168.
12. Ibe S, Shibata N, Utsumi M, and Kaneda T: Selection of human immunodeficiency virus type 1 variants with an insertion mutation in the p6^{gag} and p6^{pol} genes under highly active antiretroviral therapy. *Microbiol Immunol* 2003; 47:71–79.
13. Los Alamos HIV Sequence Database: <http://www.hiv.lanl.gov/content/sequence/HIV/mainpage.html>.
14. Katzenstein D: Diversity, drug resistance, and the epidemic of subtype C HIV-1 in Africa. *J Infect Dis* 2006;194:S45–50.

15. Herbeck JT, Lyagoba F, Moore SW, *et al.*: Prevalence and genetic diversity of HIV type 1 subtypes A and D in women attending antenatal clinics in Uganda. *AIDS Res Hum Retroviruses* 2007;23:755–760.
16. Baker CA, Bousheri S, Ssewanyana I, *et al.*: HIV subtypes distribution and implication for antiretroviral treatment in a Ugandan population. *J Int Assoc Phys AIDS Care* 2007; 6:260–263.
17. Trask SA, Derdeyn CA, Fideli U, *et al.*: Molecular epidemiology of human immunodeficiency virus type 1 transmission in a heterosexual cohort of discordant couples in Zambia. *J Virol* 2002;76:397–405.
18. Bello G, Guimarães ML, and Morgado MG: Evolutionary history of HIV-1 subtype B and F infections in Brazil. *AIDS* 2006;20:763–768.
19. Eyer-Silva WA, Couto-Fernandez JC, and Morgado MG: Molecular epidemiology of HIV type 1 in inner Rio De Janeiro State, Brazil. *AIDS Res Hum Retroviruses* 2007;23:303–308.
20. Varela RB, Ferreira SB, de Castro MB, Zalis MG, and Tavares MD: Human immunodeficiency virus type 1 protease and reverse transcriptase mutation patterns among treatment-naïve patients in different stages of infection in Rio de Janeiro, Brazil. *J Med Virol* 2007;79:1033–1039.
21. Tovanabutra S, Watanaveeradej V, Viputtikul K, *et al.*: A new circulating recombinant form, CRF15_01B, reinforces the linkage between IDU and heterosexual epidemics in Thailand. *AIDS Res Hum Retroviruses* 2003;19:561–567.
22. Tee KK, Li XJ, Nohtomi K, Ng KP, Kamarulzaman A, and Takebe Y: Identification of a novel circulating recombinant form (CRF33_01B) disseminating widely among various risk populations in Kuala Lumpur, Malaysia. *J Acquir Immune Defic Syndr* 2006;43:523–529.
23. Tovanabutra S, Kijak GH, Beyrer C, *et al.*: Identification of CRF34_01B, a second circulating recombinant form unrelated to and more complex than CRF15_01B, among injecting drug users in northern Thailand. *AIDS Res Hum Retroviruses* 2007;23:829–833.
24. Ibe S, Hotta N, Takeo U, *et al.*: Prevalence of drug-resistant human immunodeficiency virus type 1 in therapy-naïve patients and usefulness of genotype testing. *Microbiol Immunol* 2003;47:499–505.
25. Ibe S, Hattori J, Fujisaki S, *et al.*: Trend of drug-resistant HIV type 1 emergence among therapy-naïve patients in Nagoya, Japan: An 8-year surveillance from 1999 to 2006. *AIDS Res Hum Retroviruses* 2008;24:7–14.

Address reprint requests to:

Tsuguhiro Kaneda

Clinical Research Center

National Hospital Organization Nagoya Medical Center

Sannomaru 4-1-1

Naka-ku, Nagoya, Aichi 460-0001, Japan

E-mail: kanedat@nnh.hosp.go.jp

Analysis of Near Full-Length Genomic Sequences of Drug-Resistant HIV-1 Spreading among Therapy-Naïve Individuals in Nagoya, Japan: Amino Acid Mutations Associated with Viral Replication Activity

Shiro Ibe, Urara Shigemi, Kaori Sawaki, Seiichiro Fujisaki, Junko Hattori, Yoshiyuki Yokomaku,
Naoto Mamiya, Motohiro Hamaguchi, and Tsuguhiro Kaneda

Abstract

We analyzed a total of 12 near full-length genomes of drug-resistant HIV-1 spreading among therapy-naïve individuals in Nagoya, Japan. Genomes comprised seven protease inhibitor (PI)-resistant viruses possessing an M46I ($n = 6$) or L90M mutation ($n = 1$) and five non-nucleoside reverse transcriptase inhibitor-resistant viruses possessing a K103N mutation. All 12 viruses conserved both an H87Q mutation in the cyclophilin A-binding site of Gag p24 (capsid) and a T23N mutation in the cysteine-rich domain of Tat protein. PI-resistant viruses commonly possessed two cleavage site mutations in the p6^{Pol}/protease of Pol polyprotein (F48L in p6^{Pol}) and the anchor/core domains of Nef protein (L57V). These amino acid mutations represent candidates for enhancing replication activity of drug-resistant viruses and supporting expansion of such viruses in therapy-naïve individuals.

TRANSMISSION OF DRUG-RESISTANT HIV-1 in therapy-naïve individuals represents a serious problem in therapy, as such variants hinder antiretroviral therapy from the start.^{1,2} Drug-resistant viruses were detected in 27 of 402 therapy-naïve patients (6.7%) in Nagoya, Japan, between 1999 and 2006.³ Importantly, phylogenetic analysis has revealed that two main independent drug-resistant strains have been spreading in this area. One is a protease inhibitor (PI)-resistant strain possessing an M46I or L90M mutation in the protease. This strain started spreading in 2000 and was found in a total of 13 therapy-naïve patients. The other is a non-nucleoside reverse transcriptase inhibitor (NNRTI)-resistant strain possessing a K103N mutation in the reverse transcriptase. This strain started spreading in 2003 and was found in a total of five therapy-naïve patients.³ Importantly, both strains are still growing. We recently started studying why or how these drug-resistant strains can spread in therapy-naïve individuals while maintaining drug-resistant amino acid mutations that generally confer replicative disadvantages. This study analyzed near full-length genomic sequences of drug-resistant viruses to identify clues to better understanding these epidemics.

Subjects comprised a total of 12 therapy-naïve patients. Among these, seven patients were identified with PI-resistant HIV-1 possessing an M46I mutation ($n = 6$) or L90M mutation ($n = 1$). The remaining five patients displayed NNRTI-resistant HIV-1 possessing a K103N mutation by routine genotypic drug-resistance testing from 2000 to 2006.³ Genomic sequencing of HIV-1 was performed using plasma samples obtained at the first medical examination. HIV-1 RNA was purified from a plasma sample using a QIAamp viral RNA mini kit (QIAGEN, Tokyo, Japan). A single DNA fragment containing *gag* to *nef* genes was reverse transcribed and amplified by reverse transcription (RT)-nested polymerase chain reaction (PCR) using the Superscript III one-step RT-PCR system with platinum Taq high-fidelity kit (Invitrogen, Tokyo, Japan) and LA Taq polymerase (Takara, Shiga, Japan). Sense and antisense primers for RT-PCR were INF-13 and LTR-E, respectively. Sense and antisense primers for nested PCR were INF-12 and LTR-D, respectively. INF-19 or INF-11 primers were sometimes used instead of INF-13, and INF-20 or INF-10 primers were sometimes used instead of INF-12. Nucleotide sequences of primers were as follows: INF-13, 5'-GGT GAG TAC GCC ATT TAT TTG ACT




FIG. 1. Phylogenetic analysis of drug-resistant HIV-1. A phylogenetic tree was constructed using the neighbor-joining method with near full-length genomic sequences. Bootstrap values were calculated by 1,000 analyses and values greater than 70% were shown at the nodes of the tree. Scale bar represents nucleotide substitutions per site. Group O_MVP5180 was used as the outgroup. PI-resistant viruses possessing an M46I or L90M mutation are shown with closed or open triangles, respectively. NNRTI-resistant viruses possessing a K103N mutation are shown with closed squares. PI, protease inhibitor; NNRTI, non-nucleoside reverse transcriptase inhibitor.

AG-3'; LTR-E, 5'-CTT ATA TGC AGC TTC TGA GGG C-3'; INF-12, 5'-ATT TAT TTG GCG CGC GGA GGC TAG AA-3'; LTR-D, 5'-GCA TCA TTA ATT AAC CCT GGA AAG TCC CCA GCG GAA-3'; INF-19, 5'-GGT GAG TAC GCC AAA AAA CTT TTG ACT AG-3'; INF-20, 5'-AAA CTT TTG GCG CGC GGA GGC TAG AA-3'; INF-11, 5'-TCT CTC GAC GCA GGA CTC GGC TTG-3'; INF-10, 5'-GCT GAA GCG

CGC ACA GCA AGA GGC GAG-3'. The RT-PCR program consisted of one cycle of RT reaction (60 min at 50°C), 1 cycle of pre-PCR (2 min at 94°C), and 40 cycles of PCR (15 s at 94°C, 30 s at 50°C, and 10 min at 68°C). The nested PCR program consisted of one cycle of pre-PCR (2 min at 94°C) and 40 cycles of PCR (15 s at 94°C, 30 s at 50°C, and 10 min at 70°C). A labeling reaction for DNA sequencing was per-

A Pol polyprotein			B Nef protein		
AA#	p6 ^{Pol}	Protease	AA#	Anchor domain	Core domain
		48 ▼			57 ▼
NL4-3	VSFSF	PQITL	NL4-3	ACAWL	EAQEE
HXB2	...N.	..V..	HXB2
117	I...L	117	DR..V
134	..LNL	134	DR..VD
194	I..NL	194	D...VD
197	I..NL	197	D...VD
227	..L.L	227	X ₂ ..V
426	..LNL	426	.R..V
436	I...L	436	DR..V
285	285	D.V..	..H.D
329	329	D.V..	..H.D
398	398	D.V..	..H.D
472	472	D.V..D
574	574	D.V..	..H.D
C Gag p24 (capsid)			D Tat protein		
AA#	87		AA#	23	
NL4-3	PVHAGPIAP		NL4-3	CTNCYCKKCCFHCQVC	
HXB2		HXB2	
117	..Q.....		117	.N.....L.....	
134	.AQ.....		134	.N.....	
194	.AQ.....		194	.N.....Y...A.	
197	.AQ.....		197	.N.....Y.....	
227	..Q.....		227	.N.....L.....	
426	.PQ.....		426	.N.....S.....	
436	.AQ...X..		436	.N.....W.....	
285	.AQ...HP.		285	.N.....	
329	.AQ...HP.		329	.N.....	
398	.AQ...HP.		398	.N.....	
472	.AQ...HP.		472	.N.....	
574	.AQ...HP.		574	.N.....	

FIG. 2. Candidates for amino acid mutations that possibly enhance the replication activity of drug-resistant HIV-1. Protease inhibitor-resistant HIV-1 commonly possessed an F48L mutation in the carboxyl terminus of p6^{Pol} (A) and an L57V mutation in the carboxyl terminus of Nef anchor domain (B). All drug-resistant viruses displayed conservation of an H87Q mutation in the cyclophilin A-binding domain (Pro85 to Pro93) of Gag p24 (capsid) (C). All drug-resistant viruses also conserved a T23N mutation in the cysteine-rich domain (Cys22 to Cys37) of Tat protein (D). Candidate mutations are shown in bold. Cleavage points are represented as triangles in A and B. Mixed-type amino acids are represented as follows: X₁, D/A; X₂, R/C; and X₃, V/I. Amino acid sequences of NL4-3 and HXB2 were used as references. AA#, amino acid number.

formed using the BigDye terminator cycle sequencing kit (Applied Biosystems, Tokyo, Japan), and DNA sequences were determined using an ABI PRISM 310 Genetic Analyzer (Applied Biosystems). In phylogenetic analyses, multiple sequence alignment was performed using CLUSTAL W, and genetic distances were calculated based on the Kimura two-parameter model using MEGA software version 3.1.⁴ Phylogenetic trees were constructed using the neighbor-joining method with 1,000 bootstrap analyses. Genomic sequences of reference HIV-1 strains were obtained from the HIV sequence database in the Los Alamos National Laboratory.⁵ Recombinant formation was checked using the Recombinant Identification Program version 3.0 in the HIV sequence database.

A total of 12 near full-length genomic sequences of drug-resistant HIV-1 were successfully obtained from therapy-naïve patients. Seven PI-resistant viruses and five NNRTI-resistant viruses separately clustered together with reference subtype B viruses on a phylogenetic tree (Fig. 1). This is consistent with our previous result obtained by phylogenetic analysis using *pol* gene fragment alone.³ We separately confirmed that they were subtype B and not recombinant forms using the Recombination Identification Program (data not shown).

We and others have previously reported that acquisition of an M46I, L90M, or K103N major mutation enables HIV-1 to survive under pharmacotherapeutic pressure but simultaneously sacrifices the replicative activity of such viruses in the absence of drug.^{6,7} This fact forced us to hypothesize that our drug-resistant viruses restored reduced replication activity by acquiring some mutations in the genome, which thus consequently survive and expand under drug-free conditions such as in therapy-naïve patients. We therefore extensively searched for candidate amino acid mutations that might offer advantages in viral replication, revealing four interesting mutations.

The first was an F48L mutation located in the carboxyl terminus of p6^{Pol}, and the second one was an L57V mutation located in the carboxyl terminus of the Nef anchor domain (Figs. 2A, 2B). These were specified in the PI-resistant HIV-1 strain. Findings of A431V, L449F, and P453 mutations in the p7/p1 and p1/p6^{Gag} cleavage sites of Gag polyprotein, and associated restorative activities on viral replication of PI-resistant HIV-1 have been reported,^{8,9} but our viruses displayed no such mutations. The F48L mutation in p6^{Pol} and/or the L57V mutation in the Nef protein might have restoration activity in our PI-resistant viruses.

The third was a non-cleavage site mutation found in Gag p24 (capsid). Several amino acid mutations in the non-cleavage site of Gag polyprotein have been reported to restore reduced replication activity of PI-resistant HIV-1.¹⁰ One of these is an H219Q mutation also known as an H87Q mutation in the capsid. Amino acid 87H is located in the cyclophilin A-binding site, and the H87Q mutation reduces incorporation of cyclophilin A into HIV-1 virions, thus elevating HIV-1 replication.¹¹ Interestingly, all our drug-resistant viruses commonly possessed the H87Q mutation in the capsids, suggesting that replicative activities were enhanced by this mutation (Fig. 2C). Notably, in addition to the H87Q mutation, V86A/P, I91H/V, and A92P mutations were frequently found in the cyclophilin A-binding site. These additional mutations may also be associated

with viral replication activity through binding modulation to cyclophilin A.

The fourth was again a non-cleavage site amino acid mutation found in the cysteine-rich domain of Tat protein. A previous study reported T23N as a polymorphic mutation that increased Tat transactivation activity on HIV-1 provirus gene expression.¹² Interestingly, all our drug-resistant viruses also commonly possessed this T23N mutation (Fig. 2D). Elevated Tat activity may plausibly support the replication of drug-resistant viruses.

As another interesting mutation, we found an insertion mutation of RPEP in the PTAPP motif of p6^{Gag} in four cases of NNRTI-resistant HIV-1 (data not shown). At present, whether this insertion mutation confers any advantage for NNRTI-resistant viruses to survive under drug-free conditions is unclear.¹³⁻¹⁵

In conclusion, we successfully found primary candidates of amino acid mutations that might enhance the replicative activity of drug-resistant HIV-1 for surviving under drug-free conditions. Further investigations are required to elucidate whether these mutations substantially support the replication of drug-resistant viruses. Preliminary findings from our recent experiments have demonstrated positive roles of such mutations, particularly for H87Q mutation in the capsid.

Acknowledgments

J.H. is a research resident of the Japanese Foundation for AIDS Prevention. This study was partly supported by a Health Science Research Grant for Research on HIV/AIDS from the Ministry of Health, Labour and Welfare of Japan (No. H16-AIDS-002 to T.K.). Genomic sequences of PI-resistant HIV-1 and NNRTI-resistant HIV-1 have been registered in the DNA databank of Japan (DDBJ) as #AB428551-AB428557 and #AB428558-AB428562, respectively.

References

- Grant RM, Hecht FM, Warmerdam M, *et al.*: Time trends in primary HIV-1 drug resistance among recently infected persons. *JAMA* 2002;288:181-188.
- Little SJ, Holte S, Routy JP, *et al.*: Antiretroviral-drug resistance among patients recently infected with HIV. *N Engl J Med* 2002;347:385-394.
- Ibe S, Hattori J, Fujisaki S, *et al.*: Trend of drug-resistant HIV type 1 emergence among therapy-naïve patients in Nagoya, Japan: an 8-year surveillance from 1999 to 2006. *AIDS Res Hum Retroviruses* 2008;24:7-14.
- Kumar S, Tamura K, Nei M: MEGA3: Integrated software for molecular evolutionary genetics analysis and sequence alignment. *Brief Bioinform* 2004;5:150-163.
- Leitner T, Korber B, Daniels M, Calef C, Foley B: HIV-1 subtype and circulating recombinant form (CRF) reference sequences, 2005. In: *HIV Sequence Compendium 2005* (Leitner T, Foley B, Hahn B, *et al.*, eds.). Theoretical Biology and Biophysics Group, Los Alamos National Laboratory, Los Alamos, 2005, pp. 41-48.
- Ibe S, Fujisaki S, Fujisaki S, Morishita T, Kaneda T: Quantitative SNP-detection method for estimating HIV-1 replicative fitness: application to protease inhibitor-resistant viruses. *Microbiol Immunol* 2006;50:765-772.
- Gatanaga H, Hachiya A, Kimura S, Oka S: Mutations other than 103N in human immunodeficiency virus type 1 reverse

- transcriptase (RT) emerge from K103R polymorphism under non-nucleoside RT inhibitor pressure. *Virology* 2006; 344:354–362.
8. Doyon L, Croteau G, Thibeault D, Poulin F, Pilote L, Lamarre D: Second locus involved in human immunodeficiency virus type 1 resistance to protease inhibitors. *J Virol* 1996;70: 3763–3769.
 9. Maguire MF, Guinea R, Griffin P, *et al.*: Changes in human immunodeficiency virus type 1 Gag at positions L449 and P453 are linked to I50V protease mutants in vivo and cause reduction of sensitivity to amprenavir and improved viral fitness in vitro. *J Virol* 2002;76:7398–7406.
 10. Gatanaga H, Suzuki Y, Tsang H, *et al.*: Amino acid substitutions in Gag protein at non-cleavage sites are indispensable for the development of a high multitude of HIV-1 resistance against protease inhibitors. *J Biol Chem* 2002;277: 5952–5961.
 11. Gatanaga H, Das D, Suzuki Y, Yeh DD, Hussain KA, Ghosh AK, Mitsuya H: Altered HIV-1 Gag protein interactions with cyclophilin A (CypA) on the acquisition of H219Q and H219P substitutions in the CypA binding loop. *J Biol Chem* 2006;281:1241–1250.
 12. Reza SM, Shen LM, Mukhopadhyay R, Rosetti M, Pe'ery T, Mathews MB: A naturally occurring substitution in human immunodeficiency virus Tat increases expression of the viral genome. *J Virol* 2003;77:8602–8606.
 13. Peters S, Muñoz M, Yerly S, *et al.*: Resistance to nucleoside analog reverse transcriptase inhibitors mediated by human immunodeficiency virus type 1 p6 protein. *J Virol* 2001;75: 9644–9653.
 14. Ibe S, Shibata N, Utsumi M, Kaneda T: Selection of human immunodeficiency virus type 1 variants with an insertion mutation in the p6^{gag} and p6^{pol} genes under highly active antiretroviral therapy. *Microbiol Immunol* 2003;47:71–79.
 15. Tamiya S, Mardy S, Kavlick MF, Yoshimura K, Mistuya H: Amino acid insertions near Gag cleavage sites restore the otherwise compromised replication of human immunodeficiency virus type 1 variants resistant to protease inhibitors. *J Virol* 2004;78:12030–12040.

Address reprint requests to:

Tsuguhiro Kaneda
Clinical Research Center
National Hospital Organization Nagoya Medical Center
Sannomaru 4-1-1, Naka-ku, Nagoya
Aichi 460-0001, Japan

E-mail: kanedat@nnh.hosp.go.jp

Correspondence

AIDS 2009, 23:433–435

Successful genotype-tailored treatment with small-dose efavirenz

King and Aberg [1] recently published an excellent review of the clinical implications of population differences and genomic variations in efavirenz (EFV) treatment. They elegantly summarized the relationship between EFV concentration under standard dosage (600 mg once daily) and the genotype of cytochrome p450 2B6 (CYP2B6), a primary liver enzyme in EFV metabolism. They also highlighted the importance of CYP2B6 516 G>T SNP as a marker of individuals at risk of high EFV concentration and potential development of central nervous system (CNS) side-effects. However, it is desirable to discuss possible personalization of treatment by EFV dose modification.

As we described in our recent clinical study [2], we reduced EFV dosage in 12 patients with CYP2B6 516G>T polymorphism who were found to have extremely high EFV concentrations when treated with the standard dosage. The dosage was reduced from 600 to 400 mg in five individuals and to 200 mg in seven, and their HIV-1 load was successfully suppressed below detection limit (50 copies/ml) at these dosages. Interestingly, nine of the 12 suffered from chronic CNS-related symptoms at the standard dosage, but these improved in all nine by EFV dose reduction. An example of these patients is a 71-year-old man who reported having nightmares almost every night since starting EFV-containing antiretroviral therapy at 600 mg 3 years ago (Fig. 1). Plasma EFV concentrations were extremely high




Fig. 1. Efavirenz dose reduction resulted in reduced efavirenz concentration and improved central nervous system related symptom. A CYP2B6 516T/T genotype holder reported having nightmares every night for 3 years, which disappeared after efavirenz (EFV) dose reduction.

and analysis of the 516G>T SNP showed CYP2B6 516 genotype T/T. The EFV dosage was reduced to 400 mg. This resulted in a dramatic change in dream contents from nightmares to pleasant dreams. These changes occurred although the EFV concentration remained high at 400 mg. Therefore, we further reduced the dose to 200 mg. The second reduction resulted in complete disappearance of dreams. Although he missed the dreams, the EFV concentration decreased to within the target range at 200 mg. The EFV dose has been at 200 mg for more than 2 years, and the HIV-1 load remains under detection limit.

Hasse *et al.* [3] also reported a patient with genotype CYP2B6 516T/T, who had chronic CNS symptoms and extremely high EFV concentration at 600 mg dose, but the symptoms resolved by reducing the EFV dose to 200 mg. Considered together, the above report and our study suggest that the quality of life of CYP2B6 516T/T genotype holders who suffer from CNS-related symptoms can be improved by reducing EFV dose from the standard to 400 or even 200 mg. In their review, King and Aberg [1] indicated that the cost remains an issue for identifying CYP2B6 516 genotype. However, one Japanese commercial laboratory has already developed a CYP2B6 516 genotype detection system based on the Invader assay [4], which costs only ¥8000 (~\$75) per single test. Thus, the financial benefits of reducing EFV dosage should compensate for the cost of genotyping. Further large-scale studies are needed to discuss genotype-based tailored EFV treatment.

Hiroyuki Gatanaga and Shinichi Oka, AIDS Clinical Center, International Medical Center of Japan, Tokyo, Japan.

Correspondence to **Hiroyuki Gatanaga, MD**, AIDS Clinical Center, International Medical Center of Japan, 1-21-1 Toyama, Shinjuku-ku, Tokyo 162-8655, Japan. Tel: +81 3 3202 7181; fax: +81 3 5273 6483; e-mail: hingatana@imcj.acc.go.jp

Received: 5 September 2008; accepted: 12 September 2008.

References

1. King J, Aberg JA. **Clinical impact of patient population differences and genomic variation in efavirenz therapy.** *AIDS* 2008; 22:1709–1717.

2. Gatanaga H, Hayashida T, Tsuchiya K, Yoshino M, Kuwahara T, Tsukada H, *et al.* **Successful efavirenz dose reduction in HIV type 1-infected individuals with cytochrome P450 2B6 *6 and *26.** *Clin Infect Dis* 2007; **45**:1230–1237.
3. Hasse B, Gunthard HF, Bleiber G, Krause M. **Efavirenz intoxication due to slow hepatic metabolism.** *Clin Infect Dis* 2005; **40**:e22–e23.
4. Mein CA, Barratt BJ, Dunn MC, Siegmund T, Smith AN, Esposito L, *et al.* **Evaluation of single nucleotide polymorphism typing with invader on PCR amplicon and its automation.** *Genome Res* 2002; **10**:330–343.

DOI:10.1097/QAD.0b013e32831940e3

High-risk status of HIV-1 infection in the very low epidemic country, Mongolia, 2007

J Davaalkham MD*†, P Unenchimeg MD‡, Ch Baigalmaa MD‡, B Oyunbileg MD‡, K Tsuchiya PhD*, A Hachiya MS*, H Gatanaga MD PhD*†, D Nyamkhuu MD PhD‡ and S Oka MD PhD*†

*AIDS Clinical Center, International Medical Center of Japan, Tokyo, Japan; †Center for AIDS Research, Kumamoto University, Kumamoto, Japan; ‡National Center for Communicable Diseases, Ministry of Health, Ulaanbaatar, Mongolia

Summary: Thirty-six HIV-1 cases had been reported by December 2007 in Mongolia. Therefore, Mongolia has been regarded as a very low HIV-1 epidemic country, although the surveillance system is not fully developed. The aim of this study was to evaluate the risk status of HIV-1 infection in Mongolia. A total of 1415 blood samples from high-risk populations including female sex workers, men who have sex with men, mobile men, tuberculosis patients and male sexually transmitted infection (STI) clinic clients and 1050 samples from healthy controls were collected. The seroprevalences of anti-HIV-1/2, anti-*Treponema pallidum*, hepatitis B surface antigen (HBs Ag), anti-hepatitis C virus and hepatitis B surface antibody in the high-risk populations were 0%, 23.1%, 15.5%, 8.0% and 48.2%, and those in the controls were 0%, 3.1%, 14.7%, 4.4% and 44.4%, respectively. HIV-1 prevalence is currently low. However, according to the high prevalence of STIs in the high-risk populations, the risk status for HIV-1 infection is estimated to be high.

Keywords: seroprevalence of HIV, syphilis, HCV and HBV, high-risk population, Mongolia

INTRODUCTION

Mongolia is located in Central Asia bordered by Russia and China. The population of Mongolia is 2635 million, of which 61.0% live in cities and the remaining are nomadic.¹ Geographical conditions and a very low population density make communication, transport and health service provision difficult. Mongolia has witnessed radical changes in its economic and social policies since the democratic revolution of 1990. Along with independence from the former Soviet Union and loss of Soviet support, there has been an increase in unemployment, alcoholism and prostitution and a steady increase in the prevalence of sexually transmitted infections (STIs) and other communicable diseases.²⁻⁸ A recent study demonstrated that syphilis, gonorrhoea and trichomonas were detected in 57 (43%), 18 (14%) and 37 (28%) subjects, respectively, among 132 low-income female commercial sex workers (FSWs) in Mongolia.⁹ Mongolia also has a high prevalence of hepatitis B and C viral infection. In a previous study, hepatitis B surface antigen (HBs Ag) and antibodies to hepatitis C virus (anti-HCV) were detected in 24 (10%) and 41 (16%) subjects, respectively, among 249 apparently healthy individuals in Mongolia.¹⁰ However, most of these data were obtained from convenient or non-generalized samples. There is a lack of information regarding exposures and the burden of diseases in the

high-risk populations for HIV and STIs. High-risk populations such as FSWs and their sexual contacts with high rates of STIs are important populations contributing to the transmission of HIV and other STIs in developing countries.¹¹⁻¹³

Since 1992, when data on HIV/AIDS began to be compiled in Mongolia, there had been only five cases reported as of December 2004. Mongolia is considered as an HIV/AIDS low-prevalence country. However, annual new cases of HIV/AIDS have been increasing in recent years. For example, 11, 9 and 11 new cases were detected in 2005, 2006 and 2007, respectively. Among them, 22 (61.1%) cases were men who have sex with men (MSM), seven (19.4%) were heterosexually transmitted and six (16.7%) were FSWs (Mongolian National Center for Communicable Diseases [NCCD], unpublished data). Owing to the lack of a sound surveillance system, the actual situation is uncertain. The primary objective of this study was to evaluate the current risk status of HIV-1 among high-risk populations in Mongolia, examining the seroprevalence of other STIs concomitantly. These data are crucial for taking future preventive measures against HIV-1 infection.

METHODS

Study design and study population

This study was conducted from September through December 2007. The study protocol was approved by the ethics committees of the International Medical Center of Japan (H19-448) and of the Ministry of Health, Mongolia. After explaining this study and obtaining informed consent, blood samples were

Correspondence to: Dr S Oka MD PhD, AIDS Clinical Center, International Medical Center of Japan, 1-21-1, Toyama, Shinjuku-ku, Tokyo 162-8655, Japan
Email: oka@imcj.hosp.go.jp



Figure 1 A map of Mongolia. Blood samples were collected from the capital city Ulaanbaatar and four aimags (provinces), such as Darkhan-Uul, Huvsgul, Dornod and Dornogobi. Asterisks indicate the sites where blood samples were obtained

collected anonymously from both high-risk and healthy control populations in Ulaanbaatar (the capital city of Mongolia) and four aimags including Dornod, Huvsgul (borders of Russia), Dornogobi (a border of China) and Darkhan-Uul (Figure 1). A total of 2465 samples were collected: 1415 samples from high-risk populations and 1050 samples from healthy control populations. The high-risk populations included FSWs, MSM, mobile men, tuberculosis (TB) patients and male STI clinic clients. The number of samples in each population and demographic characteristics are listed in Table 1.

Cluster sampling was used for FSWs in locations such as bars, nightclubs, sauna and massage parlours serving as clusters. MSM were sampled only from Ulaanbaatar city, due to the limited data on MSM in other areas of the country. Mobile men were sampled from Ulaanbaatar city and Dornogobi aimag (province), along major road and rail networks and areas such as truck stops and checkpoints at borders. As for TB patients, those who were diagnosed with TB for the first time during the sampling period were enrolled. A male STI clinic client was defined as one who attended public STI clinics during the sampling period. A healthy control group included youth and blood donors. Youth was defined as unmarried, 15–35 years old students in college or university of both sexes. The blood donors were selected in health facilities during the sampling period.

Specimen collection and serology

All sera were stored below -20°C until use. Sera were tested for antibodies to HIV-1/2 (anti-HIV-1/2), *Treponema pallidum* (anti-TP), hepatitis B surface antibody (HBs Ab), and hepatitis C virus (anti-HCV) and HBs Ag by using the chemiluminescent enzyme immunoassay (CLEIA) (Lumipalus, Fujirebio, Tokyo,

Japan) according to the instructions provided by the manufacturer. Seropositive samples for anti-HIV-1/2 by CLEIA were further confirmed by chemiluminescent immunoassay (Architect, Abbott Laboratories, Abbott Park, IL, USA) and a Western blot for the final diagnosis. All laboratory analyses were performed at the AIDS Clinical Center, International Medical Center of Japan.

Statistical analyses

Differences among high-risk and/or healthy control populations were examined by the Fisher's exact test. Univariate logistic analyses were used to determine the odds ratios (OR) with corresponding 95% confidence intervals (CI). All analyses

Table 1 Demographic characteristics of persons who gave blood samples

Populations	No.	Sex M:F	Age	
			Range	Mean \pm SD
High risk				
FSWs	410	0:410	17–52	25.3 \pm 6.8
MSM	50	50:0	19–48	28.5 \pm 6.3
Male STI clients	545	545:0	15–64	29.2 \pm 7.9
TB patients	110	41:69	16–70	34.8 \pm 12.5
Mobile men	300	300:0	17–57	30.9 \pm 8.8
Subtotal	1415	936:479	15–70	28.8 \pm 8.7
Healthy controls				
Blood donors	150	101:49	18–49	28.2 \pm 9.3
Youth	900	450:450	15–35	19.9 \pm 2.6
Subtotal	1050	551:499	17–49	21.0 \pm 4.9

FSW = female commercial sex worker; MSM = men who have sex with men; TB = tuberculosis; STI = sexually transmitted infection